Roche Aktie News

From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market oppor...

Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript

Die Schweizer Großbank UBS hat Roche CH0012032048 auf "Buy" mit einem Kursziel von 384 Franken belassen.

(Im letzten Satz wurde ein fehlendes Wort ergänzt)ZÜRICH - Die Schweizer Großbank UBS hat Roche CH0012032048 auf "Buy" mit einem Kursziel von 384 Franken belassen.

Hoffman-La Roche aka Roche Holding AG delivered robust 2025 results, with core EPS up 11% CER and a resilient pharma division driving growth. RHHBY's pipeline, especially in obesity and cardiovascular, positions it as a potential third major player in the GLP-1 market. Management guides for mid-single digit sales and high-single digit core EPS growth in 2026, alongside a dividend increase.

Roche hopes to rival Eli Lilly and Novo Nordisk in the red-hot weight-loss space. The Swiss drug giant is working on four key drugs.

Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock. As pharma companies face a "patent cliff" where existing drugs lose exclusivity, the companies talked up what they have in the pipeline.

The Swiss drugmaker said it expects sales to grow in the mid-single-digit range, with core EPS growth in the high-single-digit range at constant currencies.